On April 14, the Administrative Committee of Tianjin Economic-Technological Development Area signed a cooperation memorandum with Asymchem Laboratories (Tianjin) Co., Ltd. to continuously expand the R&D and production base for chemical macromolecular innovative drug CDMO services in the area. The project is expected to involve an investment scale of 2 billion yuan. This initiative will further enhance the company's one-stop CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better meeting the diverse needs of global partners. The global TIDES innovative drug market is flourishing, with corresponding CDMO R&D and production demands continuously increasing. According to Frost & Sullivan data, the global peptide drug market size and nucleic acid therapy market size are projected to reach $210.8 billion and $31.5 billion, respectively, by 2030. CDMO enterprises with leading technology and production capacity layouts can seize the strategic opportunities in the industry. The signing of the cooperation memorandum between the Tianjin Economic-Technological Development Area Administrative Committee and Asymchem Laboratories, along with the continued investment in R&D and production facilities in the TIDES field, will comprehensively upgrade Asymchem's chemical macromolecular CDMO service capabilities, providing clients with more efficient and high-quality CMC services. Based on industry development trends, Asymchem has continuously increased its investment in technology R&D, capability building, and production capacity expansion for related drugs, achieving breakthrough development. In 2025, the revenue of Asymchem's chemical macromolecular CDMO business segment reached 1.028 billion yuan, a year-on-year increase of 123.72%. As of the end of March 2026, the value of related orders on hand increased by 127.59% year-on-year, with overseas orders accounting for 58.42% of the total. As a technology-driven company, Asymchem is firmly committed to investing in the TIDES drug field, with continuous iterations of new technologies including enzyme ligation technology, Tag-assisted liquid-phase synthesis, continuous multi-column countercurrent solvent gradient purification, PAT technology, and continuous cleavage technology. The related production capacity layout is accelerating, with the total production capacity for peptide solid-phase reaction synthesis expected to reach 69,000 liters by the end of this year. The newly constructed integrated R&D and production project for chemical macromolecular innovative drug CDMO by Asymchem Laboratories will further combine the advantages of large-scale production and diversified technologies, accelerating the transition of more innovative therapies from the laboratory to the global market. Dr. Hong Hao, Chairman and CEO of Asymchem Laboratories, stated that after years of effort, the company has achieved breakthrough progress in its TIDES business, which can be described as technology-driven and the culmination of long-term accumulation. This capacity expansion will further help Asymchem build a first-class TIDES drug CDMO business platform in the industry, contribute to the establishment of a more comprehensive full-industry innovation ecosystem in the region, and support regional economic development.
Comments